Amanat Acquisition Corp. agreed to combine with Corxel Pharmaceuticals, with closing expected in the first half of 2027. Management reported a $1,510,880 net loss from January 13, 2026 through September 30, 2026 and substantial doubt about its ability to continue as a going concern.
AMAN · Amanat Acquisition Corp.
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 13, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
The closing range uses available history since May 19, 2026; less than a full year is stored.
Latest documents
On October 25, 2026, Amanat Acquisition Corp agreed to a business combination with Corxel Pharmaceuticals, based on an implied Corxel equity value of $200,000,000. The combination is expected to close in the first half of 2027, following approvals by Amanat's shareholders and Corxel's sole stockholder. The PIPE Financing carries aggregate purchase commitments of $300 million, subject to reduction mechanisms.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Shell Companies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AMAN
this stock
Amanat Acquisition Corp.
|
$97.72M | — | — | — | 0.4% |
|
VYLR
Vylor Inc.
|
$45.22B | — | — | — | 2.1% |
|
CLUS
Cluster Group Holdings Ltd Co
|
$8.00B | — | — | — | — |
|
DMII
Drugs Made In America Acquisition II Corp.
|
$652.92M | +3.5% | — | — | 0.2% |
|
BCSS
Bain Capital GSS Investment Corp.
|
$607.94M | +3.3% | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 67.1%
- Net QoQ
- -69.8K sh
- Top holder
- Nantahala Capital Managem…
- Filed
- Nov 13, 2026
- This year
- 9
Amanat Acquisition Corp. agreed to combine with Corxel Pharmaceuticals, with closing expected in the first half of 2027. Management reported a $1,510,880 net loss from January 13, 2026 through September 30, 2026 and substantial doubt about its ability to continue as a going concern.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AMAN | -0.2% | -1.5% | -0.3% | +0.0% | — |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +5.3% | +4.8% | +5.3% | +5.3% | — |